Neu­ro­science leg­end Steve Paul re­tires; Ex­clu­sive: GSK hires ex-In­nate Phar­ma CEO for new po­si­tion

If you’re in neu­ro­science, you’ve prob­a­bly heard of him.

Few peo­ple have dipped a hand in as many neu­ro­science biotechs and gov­ern­ment re­search units as Steve Paul, and he’s go­ing out (near­ly) on top.

The decades­long CNS drug dis­cov­ery and de­vel­op­ment vet­er­an re­tired from his post as chief sci­en­tif­ic of­fi­cer and pres­i­dent of R&D at Karuna Ther­a­peu­tics on Jan. 16, just weeks af­ter ink­ing a $14 bil­lion ex­it to Bris­tol My­ers Squibb.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER